Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

0.43 

-0.12 -21.5%

as of Sep 29 '22

52 Week Range:

0.34 1.18


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 3.72
3.04
1.06
3.97
2.90
1.27
1.45
1.39
1.44
1.03
-0.36
growth rate -18.3% -65.1% 274.5% -27.0% -56.2% 14.2% -4.1% 3.6% -28.5% -100.0%
Earnings BIT -3.50
-13.51
6.81
7.59
1.79
0.83
12.06
20.54
12.96
growth rate 0.0% 100.0% 11.4% -76.5% -53.4% 1,347.9% 70.3% -36.9%
Avg.PE 76.00
12.00
60.33
60.33
60.33
60.33
growth rate -84.2% 402.8% 0.0% 0.0% 0.0%
ROA -18.75
-36.99
-41.42
88.96
-11.46
9.88
5.60
-5.32
1.84
-2.62
-22.83
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% -43.3% -100.0% 100.0% -100.0% 0.0%
ROE -22.51
-46.23
-61.65
113.73
-13.51
11.65
6.59
-26.84
15.01
-18.58
-718.14
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% -43.4% -100.0% 100.0% -100.0% 0.0%
ROIC -22.47
-42.54
-46.97
115.25
-14.18
11.26
5.93
-4.20
9.29
3.15
-23.78
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% -47.3% -100.0% 100.0% -66.1% -100.0%
Cur. Ratio 3.19
3.24
3.01
6.89
6.18
6.93
4.39
2.07
1.66
2.01
2.01
growth rate 1.6% -7.1% 128.9% -10.3% 12.1% -36.7% -52.9% -19.8% 21.1% 0.0%
Quick Ratio 2.80
2.91
2.81
6.60
5.84
5.54
3.57
1.51
1.33
1.47
1.59
growth rate 3.9% -3.4% 134.9% -11.5% -5.1% -35.6% -57.7% -11.9% 10.5% 8.2%
Leverage 1.21
1.33
1.77
1.17
1.19
1.16
1.19
9.74
6.77
7.45
growth rate 9.9% 33.1% -33.9% 1.7% -2.5% 2.6% 718.5% -30.5% 10.0%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 4.49
3.55
6.00
2.62
1.96
14.33
15.07
8.11
9.24
growth rate -20.9% 69.1% -56.4% -25.0% 630.7% 5.2% -46.2% 13.8%
Acct.Payable 3.43
3.50
5.62
2.62
2.76
9.90
6.48
8.31
11.35
growth rate 2.3% 60.4% -53.5% 5.5% 258.7% -34.6% 28.3% 36.5%
Cur.Assets 18.34
63.98
57.95
25.29
15.21
58.43
47.22
43.74
50.70
growth rate 248.8% -9.4% -56.4% -39.9% 284.1% -19.2% -7.4% 15.9%
Total Assets 21.62
65.14
59.13
26.52
29.92
204.41
163.13
151.77
130.33
growth rate 201.3% -9.2% -55.2% 12.8% 583.2% -20.2% -7.0% -14.1%
Cash 12.62
48.28
48.68
9.59
8.40
28.07
23.02
23.81
30.87
growth rate 282.5% 0.8% -80.3% -12.4% 234.3% -18.0% 3.4% 29.7%
Inventory 0.99
1.93
2.40
3.82
2.50
13.75
7.93
9.49
8.53
growth rate 94.9% 24.5% 58.9% -34.5% 449.4% -42.3% 19.7% -10.1%
Cur.Liabilities 6.10
9.29
9.37
3.65
3.47
31.11
28.44
21.76
25.19
growth rate 52.4% 0.9% -61.1% -5.0% 797.6% -8.6% -23.5% 15.8%
Liabilities 9.42
9.48
9.41
3.66
4.77
183.71
139.00
131.40
141.72
growth rate 0.6% -0.7% -61.2% 30.4% 3,753.7% -24.3% -5.5% 7.9%
LT Debt 3.33
0.19
0.04
0.01
1.04
117.39
104.99
91.36
83.37
growth rate -94.4% -77.1% -88.4% 20,660.0% 11,208.9% -10.6% -13.0% -8.8%
Equity 12.20
55.66
49.72
22.86
25.15
20.71
24.13
20.36
-11.39
growth rate 356.3% -10.7% -54.0% 10.0% -17.7% 16.5% -15.6% -100.0%
Common Shares 8.00
9.00
9.00
10.00
11.00
12.00
12.00
184.76
184.76
184.76
184.76
growth rate 12.5% 0.0% 11.1% 10.0% 9.1% 0.0% 1,439.7% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 0.23
0.22
0.33
0.37
2.61
0.30
0.08
0.56
0.22
growth rate -2.2% 48.2% 10.8% 608.2% -88.5% -72.3% 568.7% -60.4%
Cash From OA -1.74
2.64
-10.63
3.87
4.49
-3.52
2.36
24.15
20.84
growth rate 100.0% -100.0% 100.0% 16.1% -100.0% 100.0% 922.1% -13.7%
FCF per Share -1.20
-0.83
0.05
-0.48
-0.06
0.05
0.02
0.18
-0.20
1.05
1.31
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% -60.0% 800.0% -100.0% 100.0% 24.8%
Sale Purchase of Stock 0.08
4.12
1.02
0.36
0.01
growth rate 5,255.8% -75.4% -64.2% -98.1%
FCF -12.00
-5.00
-2.00
2.00
-11.00
4.00
2.00
-4.00
2.00
24.00
20.00
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% -50.0% -100.0% 100.0% 1,100.0% -16.7%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 18.41
13.06
20.50
27.04
17.52
20.00
69.55
73.78
68.91
growth rate -29.1% 57.0% 31.9% -35.2% 14.1% 247.8% 6.1% -6.6%
Op.Income -3.50
-13.51
6.81
7.59
1.79
0.83
12.06
20.54
12.96
growth rate 0.0% 100.0% 11.4% -76.5% -53.4% 1,347.9% 70.3% -36.9%
IBT -10.26
38.61
8.34
7.41
1.58
-6.34
3.43
-2.98
-29.35
growth rate 100.0% -78.4% -11.1% -78.7% -100.0% 100.0% -100.0% 0.0%
Net Income -10.38
38.59
-7.12
4.23
1.58
-6.15
3.40
-4.13
-32.21
growth rate 100.0% -100.0% 100.0% -62.6% -100.0% 100.0% -100.0% 0.0%
EPS -0.91
-1.54
-1.17
3.71
-0.65
0.36
0.12
-0.54
-0.51
-0.36
-2.83
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% -66.7% -100.0% 0.0% 0.0% 0.0%
Gross Profit 6.61
-0.53
9.46
14.27
8.84
11.36
48.05
51.48
44.46
growth rate -100.0% 100.0% 50.8% -38.1% 28.6% 323.0% 7.1% -13.6%
R&D 7.44
1.06
0.46
growth rate -85.8% -56.9%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 1.89
5.08
3.71
1.18
0.88
growth rate 168.9% -27.0% -68.1% -25.9%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 8.84
8.98
11.00
9.24
12.06
growth rate 1.6% 22.5% -16.1% 30.6%
Acct.Payable 9.68
10.07
9.25
11.35
12.47
growth rate 4.1% -8.2% 22.8% 9.8%
Cur.Assets 44.47
47.25
50.04
50.70
49.95
growth rate 6.3% 5.9% 1.3% -1.5%
Total Assets 149.72
150.06
135.04
130.33
127.38
growth rate 0.2% -10.0% -3.5% -2.3%
Cash 23.75
27.27
28.41
30.87
26.55
growth rate 14.8% 4.2% 8.7% -14.0%
Inventory 10.93
8.76
8.62
8.53
9.18
growth rate -19.9% -1.6% -1.0% 7.6%
Cur.Liabilities 22.62
23.06
22.89
25.19
26.02
growth rate 2.0% -0.8% 10.1% 3.3%
Liabilities 147.00
138.02
140.96
141.72
136.45
growth rate -6.1% 2.1% 0.5% -3.7%
LT Debt 88.46
85.57
85.82
83.37
80.53
growth rate -3.3% 0.3% -2.9% -3.4%
Equity 2.73
12.05
-5.92
-11.39
-9.07
growth rate 341.4% -100.0% 0.0% 0.0%
Common Shares 184.76
184.76
184.76
184.76
184.76
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures 0.11
0.01
0.00
0.10
0.01
growth rate -94.6% -66.7% 5,000.0% -87.3%
Cash From OA 3.10
6.77
5.46
5.52
-0.81
growth rate 118.8% -19.4% 1.0% -100.0%
Sale Purchase of Stock
growth rate
FCF 2.99
6.77
5.46
5.41
-0.82
growth rate 126.7% -19.3% -0.8% -100.0%
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 14.42
19.79
16.99
17.71
15.64
growth rate 37.2% -14.1% 4.2% -11.7%
Op.Income 1.89
5.08
3.71
1.18
0.88
growth rate 168.9% -27.0% -68.1% -25.9%
IBT -17.73
10.46
-16.96
-5.12
2.38
growth rate 100.0% -100.0% 0.0% 100.0%
Net Income -17.99
9.15
-17.77
-5.59
2.03
growth rate 100.0% -100.0% 0.0% 100.0%
Gross Profit 9.79
13.33
11.56
9.38
9.57
growth rate 36.1% -13.2% -18.9% 2.0%
R&D
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (9.47)

YOY Growth Grade:

F (3.54)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE 60.33 -1.76
EPS / Growth -0.25

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 1.0% 1.0%
Future PE 0.01 1.01 1.01
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.